Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
New quality-of-life data from the LITESPARK-022 trial show that adding belzutifan to adjuvant pembrolizumab in clear cell renal cell carcinoma (ccRCC) doesn't significantly worsen patients' day-to-day wellbeing. While side effects like anemia and low oxygen levels were more common, they were reversible and didn't translate into clinically meaningful quality-of-life declines. The combo already earned FDA approval in June 2026 for high-risk ccRCC after surgery.
Patient-reported outcome (PRO) data from the phase 3 LITESPARK-022 trial offer reassuring news for oncologists and patients weighing adjuvant therapy after kidney cancer surgery. Adding belzutifan (Welireg) to pembrolizumab (Keytruda) did produce more side effects — notably anemia and hypoxia — but these were reversible upon dose reduction or discontinuation, and critically, they didn't translate into clinically meaningful drops in quality of life (QOL) over the study period.
The findings complement earlier efficacy data showing the combination significantly improved disease-free survival (DFS) versus pembrolizumab plus placebo, supporting the FDA's June 2026 approval of the regimen for adult patients with clear cell RCC at intermediate-high or high risk of recurrence after nephrectomy. Expert Thomas Powles notes that in the adjuvant setting — where the goal is cure — short-term, reversible toxicity is a worthwhile trade-off for long-term benefit.
Key Takeaways:
Why it matters: For the roughly 60% of eligible patients who opt into adjuvant therapy, these QOL data provide meaningful reassurance that the most active regimen available doesn't come at a significant cost to everyday wellbeing.
